These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28019064)

  • 1. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.
    Sumida Y; Seko Y; Yoneda M;
    Hepatol Res; 2017 Mar; 47(4):266-280. PubMed ID: 28019064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
    Sumida Y; Yoneda M; Tokushige K; Kawanaka M; Fujii H; Yoneda M; Imajo K; Takahashi H; Eguchi Y; Ono M; Nozaki Y; Hyogo H; Koseki M; Yoshida Y; Kawaguchi T; Kamada Y; Okanoue T; Nakajima A; Jsg-Nafld JSGON
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.
    Kothari S; Dhami-Shah H; Shah SR
    J Clin Exp Hepatol; 2019; 9(6):723-730. PubMed ID: 31889754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review).
    Bica C; Sandu C; Suceveanu AI; Sarbu E; Stoica RA; Gherghiceanu F; Bohiltea RE; Stefan SD; Stoian AP
    Exp Ther Med; 2020 Sep; 20(3):2387-2391. PubMed ID: 32765720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
    Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D; Portillo-Sanchez P; Cusi K
    Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
    Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty liver disease in diabetes mellitus.
    Bhatt HB; Smith RJ
    Hepatobiliary Surg Nutr; 2015 Apr; 4(2):101-8. PubMed ID: 26005676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.
    Miao L; Xu J; Targher G; Byrne CD; Zheng MH
    Clin Mol Hepatol; 2022 Oct; 28(4):725-738. PubMed ID: 35286799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.
    Sofogianni A; Filippidis A; Chrysavgis L; Tziomalos K; Cholongitas E
    World J Hepatol; 2020 Aug; 12(8):493-505. PubMed ID: 32952876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review.
    Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Bittla P; Ramphall S
    Cureus; 2023 Sep; 15(9):e45789. PubMed ID: 37745748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.